Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
History Says This 1 ETF Could Turn $1,000 Into $38,000 in 20 Years. Here's How. If it grows at the rate it's grown over the past three years, your stake could end up worth over $400,000! (But closer to $38,000 is more likely.)
TSMC Reports Oct. 15. It's the Best Early Read on Nvidia's Next Quarter. The AI chip giant won't report for weeks. What can its chipmaker's results show investors first?
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
Atour's 2026 Outlook: Asset-Light Expansion Scales Hotel Network to 2,175 Locations This under-the-radar hospitality stock boasts a Superscore of 79 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Massive News for Chipotle and Starbucks Investors In case you forgot, the current CEO of Starbucks is the former CEO of Chipotle.
Is Coca Cola an Excellent Dividend Stock to Buy Right Now in October? Coca-Cola has a greater market share in away-from-home channels, such as restaurants.
Got $2,000? 2 Natural Gas Pipeline Stocks to Buy Before Winter. Energy Transfer and The Williams Companies are all solid midstream plays.
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
NICE Stock Analysis: Buy or Sell? A lower price alone is not enough to make a stock a buying opportunity.
Massive Update for AMD Stock Investors The best business in the world could make a poor investment if the price is too high.
I'd Put $500 Into Each of These 5 Dividend Stocks and Throw Away the Statement Because I own stocks like these, I don't worry about my brokerage statements, even though I'm invested in sectors that are currently out of favor.
Consumer Check-In & AI’s Progress Sales are down, guidance has been rough, and with oil and interest rates rising, what is the future for the consumer?
Better Artificial Intelligence Stock: Arm vs. Marvell Technology Arm commands smartphone architecture and is moving into AI CPUs; Marvell dominates data center connectivity with 32.6% net margins.
Can CoreWeave Unseat Amazon Web Services as the Top Cloud Provider? The neocloud company is a rising star, but the hyperscaler has a massive head start.
